Burkholderia cepacia complex nasal isolation in immunocompetent patients with sinonasal polyposis not associated with cystic fibrosis.
Marioni
G
G
Department of Medical and Surgical Specialties, Section of Otolaryngology, University of Padova, Padova, Italy. gino.marioni@unipd.it
Rinaldi
R
R
Staffieri
C
C
Ottaviano
G
G
Marchese-Ragona
R
R
Giacomelli
L
L
Ferraro
S M
SM
Staffieri
A
A
D000328:Adult; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019121:Burkholderia Infections / Q000188:drug therapy*; D042602:Burkholderia cepacia complex / Q000187:drug effects / Q000302:isolation & purification* / Q000472:pathogenicity; D002437:Cefazolin / Q000627:therapeutic use; D000077722:Ceftibuten; D002511:Cephalosporins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009298:Nasal Polyps / Q000382:microbiology* / Q000601:surgery; D015242:Ofloxacin / Q000627:therapeutic use; D011446:Prospective Studies; D012852:Sinusitis / Q000382:microbiology* / Q000601:surgery; D013407:Sulbactam / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C035444:sultamicillin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000667:Ampicillin; D015242:Ofloxacin; D002437:Cefazolin; D000077722:Ceftibuten; D013407:Sulbactam